A Feasibility Study of AlzLife 40 Hz Sensory Therapy in Patients with MCI and Early AD

Alzheimer’s Disease (AD) and Mild Cognitive Impairment (MCI) are debilitating diseases that affect millions of individuals and have notoriously limited treatment options. One emerging therapy, non-invasive 40 Hz sensory therapy delivered through light and sound has previously shown promise in improv...

Full description

Bibliographic Details
Main Authors: Sienna D. McNett, Andrey Vyshedskiy, Andrei Savchenko, Danijel Durakovic, George Heredia, Rael Cahn, Mikhail Kogan
Format: Article
Language:English
Published: MDPI AG 2023-07-01
Series:Healthcare
Subjects:
Online Access:https://www.mdpi.com/2227-9032/11/14/2040
_version_ 1797589124983554048
author Sienna D. McNett
Andrey Vyshedskiy
Andrei Savchenko
Danijel Durakovic
George Heredia
Rael Cahn
Mikhail Kogan
author_facet Sienna D. McNett
Andrey Vyshedskiy
Andrei Savchenko
Danijel Durakovic
George Heredia
Rael Cahn
Mikhail Kogan
author_sort Sienna D. McNett
collection DOAJ
description Alzheimer’s Disease (AD) and Mild Cognitive Impairment (MCI) are debilitating diseases that affect millions of individuals and have notoriously limited treatment options. One emerging therapy, non-invasive 40 Hz sensory therapy delivered through light and sound has previously shown promise in improving cognition in Alzheimer Disease (AD) rodent models. Small studies in humans have proven safe and tolerable, however exploration of feasibility and utility is limited. The purpose of this study is to examine the feasibility of this treatment in a human population through a smart tablet application that emits light and sound waves at 40 Hz to the user over the span of 1 h a day. Confirmation of entrainment of 40 Hz stimulation in the cerebral cortex was performed via EEG. 27 preliminary subjects with subjective cognitive complaints, Mild Cognitive Impairment, or AD were enrolled in the study; 11 participants completed 6 months of therapy. Of those that discontinued treatment, other health issues and difficulties with compliance were the most common causes. Participants were followed with Montreal Cognitive Assessment (MOCA) and Boston Cognitive Assessment (BOCA). For participants with subjective cognitive complaints, 2 of the 4 had improved MOCA score and 1 of 4 had improved BOCA score. For the participant with MCI, his MOCA score improved. For AD participants, 2 out of 6 had improved MOCA score and 3 of the 6 stayed stable, while 3 of 6 BOCA score improved. 4 of 11 participants specifically increased their MOCA scores in the Memory Index section. Of the 8 participants/caregivers able to speak to perceived usefulness of the study, 6 spoke to at least some level of benefit. Of these 6, 2 enrolled with subjective cognitive complaint, 1 had MCI, and 3 had AD. The therapy did not have reported side effects. However, those who did not finish the study experienced issues obtaining and operating a smart tablet independently as well as complying with the therapy. Overall, further exploration of this treatment modalities efficacy is warranted.
first_indexed 2024-03-11T01:01:55Z
format Article
id doaj.art-ac21d2c4c6c0405584b2e8f2a7233e97
institution Directory Open Access Journal
issn 2227-9032
language English
last_indexed 2024-03-11T01:01:55Z
publishDate 2023-07-01
publisher MDPI AG
record_format Article
series Healthcare
spelling doaj.art-ac21d2c4c6c0405584b2e8f2a7233e972023-11-18T19:33:06ZengMDPI AGHealthcare2227-90322023-07-011114204010.3390/healthcare11142040A Feasibility Study of AlzLife 40 Hz Sensory Therapy in Patients with MCI and Early ADSienna D. McNett0Andrey Vyshedskiy1Andrei Savchenko2Danijel Durakovic3George Heredia4Rael Cahn5Mikhail Kogan6Center for Integrative Medicine, George Washington University, Washington, DC 20052, USAMET, Boston University, Boston, MA 02215, USAAlzheimer’s Light, Miami, FL 33626, USAAlzheimer’s Light, Miami, FL 33626, USADepartment of Psychiatry and Behavioral Sciences, University of Southern California, Los Angeles, CA 90007, USADepartment of Psychiatry and Behavioral Sciences, University of Southern California, Los Angeles, CA 90007, USACenter for Integrative Medicine, George Washington University, Washington, DC 20052, USAAlzheimer’s Disease (AD) and Mild Cognitive Impairment (MCI) are debilitating diseases that affect millions of individuals and have notoriously limited treatment options. One emerging therapy, non-invasive 40 Hz sensory therapy delivered through light and sound has previously shown promise in improving cognition in Alzheimer Disease (AD) rodent models. Small studies in humans have proven safe and tolerable, however exploration of feasibility and utility is limited. The purpose of this study is to examine the feasibility of this treatment in a human population through a smart tablet application that emits light and sound waves at 40 Hz to the user over the span of 1 h a day. Confirmation of entrainment of 40 Hz stimulation in the cerebral cortex was performed via EEG. 27 preliminary subjects with subjective cognitive complaints, Mild Cognitive Impairment, or AD were enrolled in the study; 11 participants completed 6 months of therapy. Of those that discontinued treatment, other health issues and difficulties with compliance were the most common causes. Participants were followed with Montreal Cognitive Assessment (MOCA) and Boston Cognitive Assessment (BOCA). For participants with subjective cognitive complaints, 2 of the 4 had improved MOCA score and 1 of 4 had improved BOCA score. For the participant with MCI, his MOCA score improved. For AD participants, 2 out of 6 had improved MOCA score and 3 of the 6 stayed stable, while 3 of 6 BOCA score improved. 4 of 11 participants specifically increased their MOCA scores in the Memory Index section. Of the 8 participants/caregivers able to speak to perceived usefulness of the study, 6 spoke to at least some level of benefit. Of these 6, 2 enrolled with subjective cognitive complaint, 1 had MCI, and 3 had AD. The therapy did not have reported side effects. However, those who did not finish the study experienced issues obtaining and operating a smart tablet independently as well as complying with the therapy. Overall, further exploration of this treatment modalities efficacy is warranted.https://www.mdpi.com/2227-9032/11/14/2040Alzheimer’s DiseaseMild Cognitive Impairmentlight therapyintegrative medicinetechnologysmart device
spellingShingle Sienna D. McNett
Andrey Vyshedskiy
Andrei Savchenko
Danijel Durakovic
George Heredia
Rael Cahn
Mikhail Kogan
A Feasibility Study of AlzLife 40 Hz Sensory Therapy in Patients with MCI and Early AD
Healthcare
Alzheimer’s Disease
Mild Cognitive Impairment
light therapy
integrative medicine
technology
smart device
title A Feasibility Study of AlzLife 40 Hz Sensory Therapy in Patients with MCI and Early AD
title_full A Feasibility Study of AlzLife 40 Hz Sensory Therapy in Patients with MCI and Early AD
title_fullStr A Feasibility Study of AlzLife 40 Hz Sensory Therapy in Patients with MCI and Early AD
title_full_unstemmed A Feasibility Study of AlzLife 40 Hz Sensory Therapy in Patients with MCI and Early AD
title_short A Feasibility Study of AlzLife 40 Hz Sensory Therapy in Patients with MCI and Early AD
title_sort feasibility study of alzlife 40 hz sensory therapy in patients with mci and early ad
topic Alzheimer’s Disease
Mild Cognitive Impairment
light therapy
integrative medicine
technology
smart device
url https://www.mdpi.com/2227-9032/11/14/2040
work_keys_str_mv AT siennadmcnett afeasibilitystudyofalzlife40hzsensorytherapyinpatientswithmciandearlyad
AT andreyvyshedskiy afeasibilitystudyofalzlife40hzsensorytherapyinpatientswithmciandearlyad
AT andreisavchenko afeasibilitystudyofalzlife40hzsensorytherapyinpatientswithmciandearlyad
AT danijeldurakovic afeasibilitystudyofalzlife40hzsensorytherapyinpatientswithmciandearlyad
AT georgeheredia afeasibilitystudyofalzlife40hzsensorytherapyinpatientswithmciandearlyad
AT raelcahn afeasibilitystudyofalzlife40hzsensorytherapyinpatientswithmciandearlyad
AT mikhailkogan afeasibilitystudyofalzlife40hzsensorytherapyinpatientswithmciandearlyad
AT siennadmcnett feasibilitystudyofalzlife40hzsensorytherapyinpatientswithmciandearlyad
AT andreyvyshedskiy feasibilitystudyofalzlife40hzsensorytherapyinpatientswithmciandearlyad
AT andreisavchenko feasibilitystudyofalzlife40hzsensorytherapyinpatientswithmciandearlyad
AT danijeldurakovic feasibilitystudyofalzlife40hzsensorytherapyinpatientswithmciandearlyad
AT georgeheredia feasibilitystudyofalzlife40hzsensorytherapyinpatientswithmciandearlyad
AT raelcahn feasibilitystudyofalzlife40hzsensorytherapyinpatientswithmciandearlyad
AT mikhailkogan feasibilitystudyofalzlife40hzsensorytherapyinpatientswithmciandearlyad